MorphoSys AG: MorphoSys and Incyte Announce Swissmedic Tempo

MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell LymphomaMinjuvi

Related Keywords

Germany , Morges , Switzerland General , Switzerland , Munich , Bayern , United Kingdom , Planegg , Massachusetts , United States , Boston , Delaware , Canada , Swiss , Julia Neugebauer , Mike Akimov , Incyte Europe , Myles Clouston , Nationaler Krebsbericht , Jeanette Bressi , Thomas Biegi , Jonathan Dickinson , Christine Chiou , Hematology Am Soc Hematol Educ Program , Practice Research Clinical Haematology , Us Communications , Head Of Global Drug Development , Xencor Inc , Linkedin , Twitter , Drug Administration , Distribution Services , Exchange Commission , Public Affairs , Cancer Research United Kingdom , Kantar Market Research , Incyte Announce Swissmedic Temporary Approval , Refractory Diffuse Largeb Cell , Executive Vice President , General Manager , Global Drug Development , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Morphosy Annual Report , Loveman Executive Director , Research United , Market Research , Practice Research , Regulatory Announcements , Corporate News , Morphosys , Incyte , Nnounce , Swissmedic , Temporary , Approval , Injuvi , Tafasitamab , Combination , Lenalidomide , Treatment , Adults , Dlbcl ,